Research Meetings

Share
Print
Share
Print

Presentations from the Annual Small Cell Lung Cancer (SCLC) Research Consortium Meeting and the Consortium’s Virtual Meetings are posted as a reference.

2021

Virtual Meetings

“Measuring collaboration trends within the NCI Small Cell Lung Cancer Consortium Using Coauthorships”
Melissa Antman, PhD
Senior Scientific Program Analyst
Christine Burgess, PhD
Health Scientist Administrator
Center for Research Strategy, National Cancer Institute

“Inhibition of Karyopherin B-1 mediated nuclear import of lineage-defining transcription factors in small cell lung cancer”
Demetra Kelenis
Graduate Student, Johnson Laboratory
UT Southwestern Medical Center

“Comparative genomic analyses of high-grade neuroendocrine malignancies of gynecological origin with SCLC”
Ata Abbas, PhD
Research Scientist, Department of Medicine
Member, Developmental Therapeutics Program
Case Comprehensive Cancer Center, CWRU

“NEUROD1 predicts sensitivity to BET bromodomain inhibitor in SCLC”
Haobin Chen, MD, PhD
Physician-Scientist Early Investigator, Thoracic Surgery Branch
Center for Cancer Research, National Cancer Institute

“Profiling SCLC chemoresistance on complementary single cell platforms”
Charlie Rudin, MD, PhD
Chief, Thoracic Oncology Service
Director, Druckenmiller Center for Lung Cancer Research
Memorial Sloan Kettering Cancer Center

“CRISPR/Cas9 screens to identify protein destabilizers of ASCL1”
Matthew Oser, MD, PhD
Instructor in Medicine, Harvard Medical School
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute

“Characterizing chemo-radiation resistance in SCLC”
Christine Hann, MD, PhD
Associate Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Phuoc Tran, MD, PhD
Professor, Radiation Oncology and Molecular Radiation Sciences
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Luigi Marchionni, MD, PhD
Associate Professor of Pathology and Laboratory Medicine, Weill Cornell Medical School

“Deciphering metabolic vulnerabilities in small cell lung cancer”
Trudy Oliver, PhD
Associate Professor, Department of Oncological Sciences
Huntsman Cancer Institute, University of Utah

“Profiling mutations and transcription factor activity in SCLC patients using circulating cell-free DNA”
Joseph Hiatt, MD, PhD
Acting Instructor/Fellow, MacPherson Lab
Seattle Cancer Care Alliance
Fred Hutchinson Cancer Research Center

“CRISPR screening to identify new therapeutic vulnerabilities in SCLC”
David MacPherson, PhD
Associate Professor
Fred Hutchinson Cancer Research Center

“Tumor heterogeneity and immune environment in SCLC mouse models”
Carl Gay, MD PhD
Assistant Professor
Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Sarah Maddox Groves
PhD Candidate, Quaranta Laboratory
Chemical & Physical Biology Program

“Interrogating the role of Dll3 in histologic transformation of lung cancer”
Eric Gardner, PharmD, PhD
Postdoctoral Associate in Medicine, Varmus Laboratory
Myer Cancer Center, Weill Cornell Medicine

“Towards changing the course of a recalcitrant cancer by learning from every patient: Germline susceptibility to SCLC”
Anish Thomas, MBBS, MD

Lasker Clinical Research Scholar
Developmental Therapeutics Branch, Center for Cancer Research
National Cancer Institute

“Targeting small cell lung cancer with the first-in-class ubiquitin-activating enzyme (UAE/UBA1) inhibitor, TAK-243”
Benjamin Lok, MD, FRCPC
Clinician-Scientist, Princess Margaret Cancer Centre
Assistant Professor of Radiation Oncology, University of Toronto

“SCLC subtype-specific biomarker”
Simon Heeke, PhD
Postdoctoral Fellow, Heymach Laboratory
The University of Texas MD Anderson Cancer Center

“Differential ferroptotic responses in subtypes of small cell lung cancer”
Sylvia von Karstedt, PhD

Professor, Department of Translational Genomics, CECAD Research Center
Faculty of Medicine, University of Cologne, Germany

CRISPR screen identifies a highly effective combination treatment for SCLC”
Alvaro Quintanal-Villalonga, PhD
Research Associate, Rudin/Sen Laboratory
Memorial Sloan Kettering Cancer Center​

​”EpicMIBI: A new approach to investigate intra-tumoral heterogeneity in SCLC”
Alexandros P. Drainas, PhD
Postdoctoral Fellow, Sage Laboratory
Stanford University 

“Unique role and vulnerability of EP300 KIX in small-cell lung cancer”
Kwon Park, PhD
Associate Professor, Microbiology, Immunology & Cancer Biology
University of Virginia School of Medicine

2020

Annual Meeting

Small Cell Lung Cancer Consortium Meeting
March 26-27, 2020
Bethesda North Marriott Hotel & Conference Center
Cancelled


Virtual Meetings

“SCLC_CellMiner: Integrated genomics and therapeutics predictors of SCLC cell lines”
Yves Pommier, MD PhD
Chief, Developmental Therapeutics Branch
Head, Molecular Pharmacology Group
National Cancer Institute, National Institutes of Health

“Association of gene expression of 72 epigenetic molecular factors with DNA methylation and chemosensitivity in SCLC cell lines”
Julia Krushkal, PhD
Computational Biologist, Biometric Research Program
Computational & Systems Biology Branch
National Cancer Institute

“Acquired resistance to olaparib-temozolomide in SCLC PDX”
Marcello Stanzione, PhD
Postdoctoral Fellow, Dyson laboratory
Center for Cancer Research
Massachusetts General Hospital

“Defining putative tumor suppressors of SCLC development”
Kwon Park, PhD
Associate Professor
Microbiology, Immunology, and Cancer Biology
University of Virginia School of Medicine

“Identification of RUNX1T1 as a potential epigenetic modifier in small cell lung cancer”
Tian He
Graduate Student, Dowlati Laboratory
Case Comprehensive Cancer Center
Case Western Reserve University

“Dissecting cross-resistance in SCLC”
Benjamin Drapkin, MD, PhD
Assistant Professor
Simmons Comprehensive Cancer Center
UT Southwestern Medical Center

“Multimodal approach to circulating RNA detection in SCLC”
Patrick Nana-Sinkham, MD
Chair, Division of Pulmonary Disease & Critical Care Medicine
Virginia Commonwealth University School of Medicine
James Lee, MD PhD
Professor, Chemical & Biomolecular Engineering
The Ohio State University

“Continuous luminescence modeling to quantify growth of adherent and suspension SCLC”
Clayton Wandishin
Graduate Student, Chemical and Physical Biology Department
Vanderbilt University Medical Center

“DDR/IO combos in the world of inter- and intra-tumoral heterogeneity”
Lauren Byers, MD
Associate Professor, Department of Thoracic Head and Neck Medical Oncology
Division of Cancer Medicine
MD Anderson Cancer Center

“Recent explorations in small-land”
Charlie Rudin, MD PhD
Chief, Thoracic Oncology Service
Director, Druckenmiller Lung Center
Memorial Sloan Kettering Cancer Center

“Molecular characterization of neuroendocrine transformation in lung cancer”
Triparna Sen, PhD
Assistant Attending, Thoracic Oncology
Co-Director, Charles Rudin Lab, Molecular Pharmacology Program
Memorial Sloan Kettering Cancer Center

“Targeting delta-like ligand 3 for 177Lu-based radioimmunotherapy of SCLC”
J.T. Poirier, PhD
Assistant Professor, Department of Medicine
Director, Preclinical Therapeutics Program
Perlmutter Cancer Center, NYU Langone Health

“Diversity of pulmonary NE signals and targets revealed by scRNASeq”
Christin Kuo, MD
Assistant Professor, Department of Pediatrics
Stanford University School of Medicine

“Modeling the response of SCLC to radiation therapy”
Julien Sage, PhD
Professor, Department of Pediatrics and Genetics
Stanford University School of Medicine

“Skp2 E3 ubiquitin ligase: a downstream target in RB1-deficient SCLC”
Edward Schwartz, PhD
Professor, Department of Medicine (Oncology)
Professor, Department of Molecular Pharmacology
Albert Einstein College of Medicine

“A ubiquitin E3 ligase mediates resistance to PARP inhibitors in SCLC”
Benjamin Lok, MD
Assistant Professor, Department of Radiation Oncology
Medical Biophysics, Institute of Medical Science
Princess Margaret Cancer Centre, University of Toronto

“Genomic and transcriptomic features of relapsed SCLC”
Siddhartha Devarakonda, MD
Assistant Professor of Medicine
Siteman Cancer Center
Washington University School of Medicine

“Molecular comparison of PDX/CDX models with primary specimens”
Luc Girard, PhD
Assistant Professor, Hamon Center for Therapeutic Oncology Research
Simmons Comprehensive Cancer Center
UT Southwestern Medical Center

“Deep proteomic profiling of SCLC cell lines reveals a MYC-centric neuroendocrine signature”
Ehsan Irajizad, PhD
Biomathematics and Biostatistics
MD Anderson Cancer Center

“MYC-driven polyamine signature with a protein panel for early detection”
Johannes Fahrmann, PhD
Instructor, Clinical Cancer Prevention
MD Anderson Cancer Center

“Skp2 E3 ubiquitin ligase: a downstream target in RB1-deficient SCLC”
Edward Schwartz, PhD
Professor, Department of Medicine (Oncology)
Professor, Department of Molecular Pharmacology
Albert Einstein College of Medicine

“A ubiquitin E3 ligase mediates resistance to PARP inhibitors in SCLC”
Benjamin Lok, MD
Assistant Professor, Department of Radiation Oncology
Medical Biophysics, Institute of Medical Science
Princess Margaret Cancer Centre, University of Toronto

“Functional screens and mouse models identify MAX as a tumor suppressor in SCLC”
Arnaud Augert, PhD
Postdoctoral Fellow (MacPherson Lab)
Human Biology & Public Health Sciences Divisions
Fred Hutchinson Cancer Research Center

“Transcriptional programs and immune activation define four major subtypes of SCLC”
Carl Gay, MD PhD
Assistant Professor
Department of Thoracic/Head and Neck Medical Oncology
MD Anderson Cancer Center

“MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate”
Trudy Oliver, PhD
Associate Professor, Oncological Sciences
Huntsman Cancer Institute, University of Utah

“The tuft cell variant of SCLC”
Chris Vakoc, MD PhD
Professor, CSHL Cancer Center
Cold Spring Harbor Laboratory

“Plasticity of MHC class I expression and immune rejection”
David Barbie, MD
Associate Director, Belfer Center for Applied Cancer Research
Associate Professor, Lowe Center for Thoracic Oncology 
Dana-Farber Cancer Institute

“CDK7 inhibition potentiates genome instability triggering anti-tumor immunity”
Hua Zhang, PhD
Postdoctoral Fellow, Wong Laboratory
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health

“A new ASCL1+ subtype, A2, forms a plastic, transit-amplifying compartment of SCLC tumors”
Sarah Groves
Graduate Student, Quaranta Laboratory
Quantitative and Chemical Biology Program
Vanderbilt University School of Medicine

“Computational Modeling of Subtype Interactions in SCLC to Modulate Tumor Composition”
Leonard Harris, PhD
Department of Biochemistry
Vanderbilt University School of Medicine

“Epigenome-wide DNA methylation analysis of SCLC cell lines suggests potential chemotherapy targets”
Julia Krushkal, PhD
Biometric Research Program
Computational & Systems Biology Branch
National Cancer Institute

“On the origins of SCLC”
Harold Varmus, MD
Lewis Thomas University Professor
Meyer Cancer Center, Weill Cornell Medicine

“Histologic transformation in lung cancer through basal cell intermediates”
Eric Gardner, PharmD, PhD
Postdoctoral Fellow, Varmus Lab
Meyer Cancer Center, Weill Cornell Medicine

“scRNASeq reveals intratumoral heterogeneity in therapy resistance”
Allison Stewart, PhD
Research Scientist, Byers Laboratory
MD Anderson Cancer Center

“Novel Chemotherapy-stable subpopulations are conserved across multiple PDX models”
Jonathan Lehman MD, PhD
Instructor in Medicine, Division of Hematology/Oncology
Vanderbilt University Medical Center

2019

Annual Meeting

IASLC 2019 Small Cell Lung Cancer Meeting
April 3-5, 2019
Zuckerman Research Center
Memorial Sloan Kettering Cancer Center
Program Agenda


Virtual Meetings

“Genomic and Functional Identification of Chemotherapy Resistance Mechanisms in Small Cell Lung cancer”
Ramaswamy Govindan, MD

Anheuser Busch Endowed Chair in Medical Oncology
Professor of Medicine, Division of Oncology
Director, Section of Medical Oncology
Washington University School of Medicine, Siteman Cancer Center
Obi Griffith, PhD
Assistant Professor of Medicine, Division of Oncology
Assistant Director, McDonnell Genome Institute
Washington University School of Medicine, Siteman Cancer Center
Trudy Oliver, PhD
Associate Professor, Department of Oncological Sciences
Cell Response and Regulation Cancer Center Program
Huntsman Cancer Institute, University of Utah

“Using patient-derived models to understand drug responses in SCLC”
Anna Farago, MD PhD

Assistant Professor, Medicine, Harvard Medical School
Assistant, Medicine, Massachusetts General Hospital
Dana Farber/Harvard Cancer Institute
Benjamin Drapkin, MD, PhD
Instructor, Medicine, Massachusetts General Hospital
Nicholas Dyson, PhD
Professor of Medicine, Mary B. Saltonstall Chair in Oncology, Harvard Medical School
Geneticist, Center for Cancer Research
James and Shirley Curvey MGH Research Scholar
Scientific Director, Mass General Cancer Center

“Integrated Protometabolic Analysis Reveals Metabolic Vulnerabilities in SCLC”
Eric Haura, MD

Director, Lung Comprehensive Research Center
Co-Program Leader, Chemical Biology and Molecular Medicine Program
Department of Thoracic Oncology
H. Lee Moffitt Cancer Center & Research Institute

“Discovering tumor vulnerabilities linked to de-differentiation: Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies”
Thomas Graeber, PhD

Director, UCLA Metabolomic Center
Professor, Molecular & Medical Pharmacology
Member, Crump Institute for Molecular Imaging at UCLA
UCLA Molecular Biology Institute

“Phenotype interactions in SCLC development and detection”
Christine Lovly, MD, PhD

Co-Leader, Translational Research and Interventional Oncology Research Program
Associate Professor of Medicine (Hematology/Oncology)
Vanderbilt Ingram Cancer Center
Alissa Weaver, MD, PhD
Professor, Cell and Developmental Biology & Pathology
Microbiology, and Immunology
VU Center for Cancer Systems Biology
Vanderbilt Ingram Cancer Center

“Developing ASCL1 and NEUROD1 lineage oncogene targeted therapy for small cell lung cancer”
John Minna, MD

Director, Hamon Center for Therapeutic Oncology Research
The Moncrief Center for Cancer Genetics,
Co-Director of the Experimental Therapeutics Program, Simmons Cancer Center
Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology
Sarah M. and Charles E. Seay Distinguished Chair in Cancer Research
UT Southwestern Medical Center
Jane Johnson, PhD
Professor and Vice Chair, Department of Neuroscience
Shirley and William S. McIntyre Distinguished Chair in Neuroscience
UT Southwestern Medical Center

“Targeting BCAT1 and branched-chain amino acid metabolism for the detection and prevention of SCLC”
Kwon-Sik Park, PhD

Associate Professor, Microbiology, Immunology, and Cancer Biology
University of Virginia, School of Medicine

“RB1 WT SCLC and RB1 WT, KEAP1 WT, STK11 WT neuroendocrine negative LCNEC”
Dmitriy Sonkin, PhD

Computational Biologist, Computational & Systems Biology Branch
Division of Cancer Treatment & Diagnosis (DCTD)
National Cancer Institute

2018

Annual Meeting

Small Cell Lung Cancer Consortium Meeting
March 15-16, 2018
NCI Shady Grove, Rockville, MD
Program Agenda


Virtual Meetings

“Tissue Microarray (TMA) Project”
Afshin Dowlati, MD

Professor, Department of Medicine Division of Hematology and Oncology, School of Medicine
Member, Developmental Therapeutics Program, Case Comprehensive Cancer Center
Case Western Reserve University
Gary Wildey, PhD
Program Manager
Case Comprehensive Cancer Center
Case Western Reserve University

“RB1 Loss Drives Prostate Cancer Lineage Plasticity and Therapeutic Resistance”
Leigh Ellis, PhD

Assistant Professor, Pathology, Harvard Medical School
Assistant Professor of Pathology, Oncologic Pathology
Dana-Farber Cancer Institute, Harvard Cancer Center

“Center for Systems Biology of Small Cell Lung Cancer”
Vito Quaranta, MD

Department of Biochemistry, Professor in Biochemistry & Pharmacology
Director of Quantitative Systems Biology Center
Co-Director of The Center for Matrix Biology
Vanderbilt University

“Understanding Different Subsets of Small Cell Lung Cancer”
David MacPherson, PhD

Associate Member, Human Biology Division
Associate Member, Public Health Sciences Division
Fred Hutchinson Cancer Research Center

“Enhancing Small Cell Lung Cancer Therapy with Pharmacological Ascorbate”
Bryan Allen, MD

Associate Professor of Radiation Oncology
Carver College of Medicine
University of Iowa Health Care

“A Tuft Cell Variant of Small Cell Lung Cancer”
Chris Vakoc, MD, PhD
CSHL Cancer Center
Gene Regulation and Cell Proliferation
Cold Springs Harbor Laboratory

2017

Annual Meeting

IASLC 2017 Small Cell Lung Cancer Meeting
March 15-17, 2017
Zuckerman Research Center
Memorial Sloan Kettering Cancer Center
Program Agenda